Equasens (STU:PHF) Notes Receivable: €0.0 Mil (As of Dec. 2025)


STU:PHF Equasens STU:PHF
77 GF Score
Price €34.95
GF Value €56.88
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Equasens Notes Receivable?

Equasens STU:PHF +0.72% 77 Notes Receivable is €0.0 Mil as of Dec. 2025. GuruFocus rates STU:PHF with a GF Score™ of 77/100 and a GF Value™ of €56.88 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Equasens's Notes Receivable for the quarter that ended in Dec. 2025 was €0.0 Mil.

Equasens Notes Receivable Historical Data

* Premium members only.

The historical data trend for Equasens's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Equasens Notes Receivable Chart

Equasens Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Equasens Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:PHF
77GF Score
Equasens STU:PHF
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Equasens Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.0 Mil mean?
Equasens (STU:PHF) has a Notes Receivable of €0.0 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Equasens and its competitors.
Is Equasens' Notes Receivable too high?
Equasens' current Notes Receivable is €0.0 Mil. Overall, Equasens has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Equasens' Notes Receivable compare to VEEV and BTSG?
Equasens' Notes Receivable of €0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Healthcare Providers & Services company?
A good Notes Receivable depends on the Healthcare Providers & Services industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Equasens and its competitors. Equasens's current Notes Receivable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Based on GuruFocus' analysis, Equasens (STU:PHF) is currently considered Significantly Undervalued. The stock's GF Value™ is €56.88, compared to a current price of €34.95 — trading 38.6% below its estimated fair value. The current Notes Receivable is €0.0 Mil. Equasens' overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Equasens (STU:PHF), the current Notes Receivable is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Equasens (STU:PHF) Overvalued in 2026?

Based on GuruFocus' analysis, Equasens stock appears to be undervalued. The current stock price of €34.95 is trading 38.6% below its estimated GF Value™ of €56.88. GuruFocus considers Equasens to be Significantly Undervalued.

Key valuation signals for STU:PHF:

  • Notes Receivable: €0.0 Mil
  • GF Value™: €56.88 vs. price of €34.95 (38.6% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the STU:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Equasens Business Description

Other Exchanges EQSp:UK0R9T:UKEQS:France
Address 5 Allee de Saint-Cloud, Technopole de Nancy Brabois, Villers-les-Nancy, FRA, 54600
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
77GF Score

Get the complete analysis for STU:PHF

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.95
Price
€56.88
GF Value